Together, these strategies enhance the precision of BET targeting; yet a recent multi-tumor analysis demonstrated that adaptive BRD2 overexpression can sustain transcriptional programs and drive resistance, emphasizing the need to integrate combination or sequential therapies into future treatment approaches (39). Here, DNER is linked to neoplasm.